Peptide News Digest

#Adolescent-Obesity

3 stories

Industry · View digest

Chinese Biotech Peptide Pipeline Expanded Across the Week With Gan & Lee Pharmaceuticals Initiating a Phase II Clinical Trial of GZR102 (a Basal Insulin/GLP-1RA Fixed-Dose Weekly Formulation) on August 8, 2026 and Registering a Phase I Study of GZR18 on August 15; Xianweida Registered XW003 (Ecnoglutide) Phase I Clinical Trial for Adolescent Obesity on August 8; Wayne Biotech WBD156 Capsule Advanced Through Development; Fujian Genorup Semaglutide Pipeline Expanded; The Week's Pattern Extends the Chinese Biotech GLP-1 Ambition That Now Spans Ribupatide (Hengrui-Kailera, Global Phase 3 H1 2027), Mazdutide (Innovent, GLP-1/Glucagon Dual Agonist in Late-Stage Trials), MWN105 (Minwei Bio, Semaglutide-Intolerant Population), and IBI3032 (Innovent, FDA IND August 5)

Chinese biotech peptide pipeline expanded across the week ending August 22, 2026. Key registrations and advances: Gan & Lee Pharmaceuticals initiated a Phase II clinical trial of GZR102 (a basal insulin plus GLP-1 receptor agonist fixed-dose weekly formulation) on August 8, targeting patients requiring both basal glycemic control and appetite-and-glucose modulation from a single weekly injection; Gan & Lee also registered a Phase I study of GZR18 on August 15. Xianweida registered XW003 (ecnoglutide) Phase I clinical trial for adolescent obesity on August 8, extending the ecnoglutide franchise into pediatric obesity development after the adult Phase 3 EECOH-2 win. Wayne Biotech WBD156 capsule (oral peptide candidate) advanced through preclinical/early-clinical development. Fujian Genorup's semaglutide pipeline expanded across multiple formulation and indication programs. The week's pattern extends the broader Chinese biotech GLP-1 pipeline expansion that now spans ribupatide (Hengrui-Kailera, once-weekly injectable GLP-1/GIP/glucagon triple agonist, global Phase 3 planned H1 2027), mazdutide (Innovent, GLP-1/glucagon dual agonist in late-stage Chinese and US trials), MWN105 (Minwei Bio, targeting semaglutide-intolerant populations), IBI3032 (Innovent, FDA IND clearance August 5), and multiple additional candidates. The synchronized China+US development pattern reflects the increasing sophistication of Chinese biotech clinical strategy targeting global markets rather than China-only launches.

Research · View digest

JAMA Pediatrics Publishes UT Southwestern Retrospective Cohort Study Monday July 20, 2026 Analyzing 204,000+ US Adolescents and Young Adults Ages 13-25 Treated for Obesity Between May 2022 and January 2026 in the Epic Cosmos Electronic Health Record Database: GLP-1 Receptor Agonist Monotherapy Share Rose From 88.2% (May-November 2022) to 96.1% (June 2025-January 2026), Metabolic and Bariatric Surgery (MBS) Share Fell From 11.6% to 3.7% Over the Same Window, and Combined GLP-1 + MBS Use Remained Rare at Approximately 0.2%; Severe Obesity Currently Affects Approximately 9% of Ages 12-18 in the US

JAMA Pediatrics published a UT Southwestern Medical Center retrospective cohort study Monday July 20, 2026 examining GLP-1 receptor agonist and metabolic and bariatric surgery (MBS) utilization patterns among 204,000+ US adolescents and young adults ages 13-25 treated for obesity between May 2022 and January 2026 in the Epic Cosmos electronic health record database. Key findings: the share of patients using only GLP-1 drugs rose from 88.2% (May-November 2022) to 96.1% (June 2025-January 2026); the share of patients undergoing MBS fell from 11.6% to 3.7% over the same window; combined GLP-1 + MBS use remained rare at approximately 0.2%. The study documents a substitution effect from surgical obesity treatment toward pharmacologic obesity treatment in the youth population over 44 months of coverage. Context: severe obesity currently affects approximately 9% of US adolescents ages 12-18. The findings raise questions about long-term efficacy, weight-regain risk after GLP-1 discontinuation in adolescents, and the appropriate role of MBS in adolescents whose obesity is unresponsive to GLP-1 pharmacotherapy. The study covers the pediatric analog of the earlier adult utilization-shift patterns already documented in the Kaiser Permanente and Optum electronic health record data.

Clinical Trials · View digest

Tonix Pharmaceuticals Q1 2026: TONMYA Hits $3.7M Launch Revenue, TNX-1900 Intranasal Oxytocin Pipeline Spans Binge Eating, Adolescent Obesity, Bone Health, AVP Deficiency

Tonix Pharmaceuticals reported Q1 2026 May 11 with $6.9M total net product revenue and a $40.2M net loss. TONMYA (cyclobenzaprine HCl sublingual tablet for fibromyalgia) generated $3.7M in its first full commercial quarter on 5,400 prescriptions filled and 2,145 prescribing HCPs. The peptide-relevant pipeline continues to anchor on TNX-1900, an intranasal potentiated oxytocin candidate now in four Phase 2 investigator-initiated studies at Mass General Hospital and the University of Virginia: binge-eating disorder, adolescent obesity, bone health in autism spectrum disorder, and arginine vasopressin deficiency. The portfolio represents one of the few clinical-stage neuropeptide programs outside the GLP-1 axis, with potential applications across psychiatric, metabolic, and rare endocrine indications.